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Abstract. Introduction: Previous studies have suggested the use of soluble CD26 (sCD26) as a tumour marker for the detection
of colorectal cancer (CRC) and advanced adenomas. The aim of this study was to assess the sCD26 concentration in a large
cohort to evaluate its association to epidemiologic parameters and CRC-related symptoms/pathologies.
Subjects and methods: Serum samples were collected from 2,754 putatively healthy individuals with ages ranging from 30–65
years, and with personal or familial history of polyps, CRC and/or CR symptoms. sCD26 levels were measured by ELISA.
Results: No association was found between the sCD26 concentration and age (< 50 and  50), the personal or familial
history of polyps or CRC, rectal bleeding, haemorrhoids or diverticula. However, sCD26 was related to non-inflammatory
benign pathologies (excluding rectal bleeding, changes in bowel habits, haemorrhoids, diverticula) and to inflammatory benign
pathologies.
Discussion: Our results confirm that the sCD26 can be easily offered and evaluated in a large cohort. Additionally, the validation of
sCD26 as a tumour marker for screening and case-finding purposes requires a further comparison with an established non-invasive
test like the faecal occult blood.
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1. Introduction
The exoprotease dipeptidyl peptidase IV (DPP-IV,
EC 3.4.14.5), also called CD26, is a transmembrane
glycoprotein expressed constitutively on a variety of
cell types, particularly prostate, kidney, liver and ep-
ithelial cells, predominantly in exocrine glands and ab-
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sorptive epithelia, as well as on lymphocytes [3]. The
DPP-IV activity cleaves two N -terminal amino acids
from polypeptidic chains with proline or alanine in the
second position, which otherwise are resistant to most
proteases [4]. It participates in the process of dietary
protein assimilation and in the cleavage or clipping of
many regulatory peptides such as several chemokines,
integrins or neuropeptides [3,4]. CD26 has been de-
scribed as the adenosine deaminase (ADA) binding or
complexing protein (ADAbp, ADCP) and as a func-
tional receptor for collagen and fibronectin, although
its physiological role remains poorly understood [4,10,
14,15].
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Significant levels of DPP-IV activity have been
shown in body fluids such as plasma/serum, cere-
brospinal and synovial fluids, semen and urine [1,6].
Within the normal human plasma/serum, 90–95% of
the DPP-IV activity has been associated to the rela-
tively high concentration of CD26 (∼ 600 ng/mL) [1].
sCD26 (soluble CD26) may be shed from the plas-
ma membrane of CD26 expressing cells by proteolytic
cleavage or secretion through exosomes, although lym-
phocytes and liver bile canaliculi have been proposed
as the main source [1,6]. In an oncogenic process, in
addition to a plausible involvement in both immuno-
suppressor and angiogenic mechanisms, the process of
shedding might initiate or silence the CD26 involve-
ment in cell-adhesion processes through fibronectin,
ADA or collagen binding [6,15–17].
We have reported reduced sCD26 levels in the serum
of colorectal cancer (CRC) patients even in early stages
of the disease, which suggested its potential use for
early diagnosis [2,7]. Subsequent case-control studies
suggested that a sCD26 test could improve current non-
invasive screening tests recommended for the detection
of CRC and advanced adenomas, and could be used in
patient monitoring and prognosis [8].
The aim of this study was to measure the sCD26 con-
centration in a large cohort of presumably healthy indi-
viduals and to evaluate its association with epidemio-
logic parameters as well as certain common digestive-
related symptoms or pathologies. The information ob-
tained from this cohort will complement existing da-
ta and will be essential to determine the viability of
the sCD26 test for the diagnosis of CRC and advanced
adenomas.
2. Patients and methods
2.1. Population
The study included 2,754 putatively healthy individ-
uals from the company PSA Peugeot Citroën, work-
ing at the manufacturing centre in Vigo (Spain). Indi-
viduals were mainly males (98%), with ages ranging
from 30 to 65 years. The distribution of the individu-
als according to their age was as follows: 30–39 years
(0.1%), 40–49 years (1.3%), 50–59 years (86.8%) and
60–65 years (11.7%), resulting on an average of 55.5
± 3.6 years.
The company’s medical service informed employees
about the study, and after consent, personal question-
naires were completed for data such as personal and
familial history of colorectal polyps or cancer, bowel
diseases, symptoms, and smoking status. The final co-
hort included individuals with personal history of CRC;
personal history of a cancer other than CRC; personal
history of colorectal polyps; and familial history of can-
cer and/or colorectal polyps. Regarding their personal
history of non-CR cancer, the most common tumours
found were prostate, lung, bladder, parotid, ileum and
kidney. The symptoms and pathologies recorded were
rectal bleeding or faecal blood,changes in bowel habits,
haemorrhoids, diverticula, other non-inflammatory be-
nign pathologies including anal fissure, irritable bowel
syndrome and spastic colon, and inflammatory bowel
disease (colitis or Crohn).
For all the individuals included in the study,informed
consent was obtained and anonymity was warranted;
all procedures were performed following the tenets of
the Helsinki Declaration.
2.2. Collection of serum samples and determination
of sCD26 levels
Blood was allowed to coagulate at room temperature
for 20 min and centrifuged at 2,000 g for 15 min. Sera
were stored at −80◦C until used. Serum levels of the
sCD26 were measured with the Human sCD26 ELISA
kit (Bender Medsystems; Vienna, Austria) according to
the manufacturer’s instructions. Colorimetric quantifi-
cation was performed with a microplate reader (model
550; Bio-Rad, USA) using dual readings at 450/570
nm. The sCD26 concentration was determined from
the standard curves.
2.3. Statistical analysis
All the statistical tests, except Dunn’s, were per-
formed with the SPSS software package (release 16.0).
Data was analysed through the ANOVA test; non-
parametric analysis of more than two independent sam-
ples was done by the Kruskal-Wallis and the Dunn’s
tests for multiple comparisons.
The rate of sCD26 positive cases was calculated
on the basis of a cut-off value of 460 ng/mL ob-
tained in a previous study for no colorectal pathology,
non-inflammatory and inflammatory bowel disease and
polyp control populations vs. CRC patients (manuscript
submitted). A positive value was defined as any val-
ue equal or below the cut-off. All the statistical tests
were two-sided, and p-values < 0.05 were considered
statistically significant. For the pos hoc Dunn’s test,
significance was achieved if the differences between
mean ranks for the pair compared (in absolute values)
were larger than the Dunn’s contrast.
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Table 1
sCD26 levels (ng/mL) according to the gender and age groups in the population studied
Epidemiologic n sCD26 sCD26 sCD26 ANOVA
information range median mean ± SD p-value
Gender Male 2,699 118–3,062 522.0 554.8 ± 180.1 0.190
Female 55 335–1,820 530.0 609.6 ± 244.4
Age Gender n sCD26 sCD26 sCD26 ANOVA
(years) range median mean ± SD p-value
< 50 Male 38 422–909 522.0 567.7 ± 142.9 0.496#
Female 2 433–529 481.0 481.0 ± 67.90
 50 Male 2,661 118–3,062 522.0 554.6 ±180.6 0.088
Female 53 335–1,820 544.0 614.5 ± 247.5
sCD26 concentration in ng/mL; SD: standard deviation.
#: analysis by ANOVA not allowed; the non-parametric U test showed a p-value of 0.321.
3. Results
3.1. Soluble CD26 levels in a large cohort
The sCD26 concentration measured in the sera of
the 2,574 individuals (predominantly males over 50
years) showed a normal distribution, ranging from 118
to 3,062 ng/mL with a mean (± standard deviation)
and median value of 555.9 ± 181.7 ng/mL and 522.0
ng/mL, respectively. The range, median and mean
sCD26 concentration on the basis of gender and age are
shown in Table 1. Although only 2% (55 individuals)
of the cohort were women compared to the 2,699 men,
no statistically significant differences were detected in
the sCD26 levels (p = 0.190). However, the overall
sCD26 mean as well as the median was slightly higher
in women than in men. Regarding the age groups (< 50
years and  50 years), differences were not observed
in the sCD26 levels (p = 0.496). However, a more
detailed analysis comparing the age groups 30–39, 40–
49, 50–59 and 60–65 revealed differences in the sCD26
concentration (p = 0.038). Dunn’s test confirmed this
difference between all the paired comparisons, except
for the 40–49 years and 50-59 years. Additionally we
corroborated that, when separating males from females
into the former two groups of age, no differences in the
sCD26 levels were found (< 50 years p = 0.321 and 
50 years p = 0.088).
3.2. Relationship of sCD26 levels with CRC-related
epidemiologic parameters
After confirming no association between the sCD26
levels and the gender and age of the individuals from
this cohort, we analysed its relation with the data ob-
tained from the personal questionnaires. Table 2 sum-
marizes for all the variables studied: the sCD26 range,
median and mean for the presence or absence of each
feature. Fifty five individuals included in this cohort
(2.0%) referred a personal history of cancer (excluding
CRC), while 6 (0.2%) and 80 (2.9%) individuals had
been previously diagnosed with CRC or polyps, respec-
tively. No statistically significant differences were de-
tected comparing the sCD26 levels of individuals bear-
ing or not personal history of cancer, CRC or polyps
(p = 0.309, p = 0.995 and p = 0.408, respective-
ly). Regarding the familial history of polyps or can-
cer, no differences were found either (p = 0.809 and
p = 0.355, respectively). However, for the personal
and familial history of cancer, CRC and polyps, the
sCD26 mean in all the cases was slightly lower than
the corresponding groups without history.
Levels of the sCD26 were also analysed in relation to
certain symptoms (Table 2). Although the individuals
from this cohort were presumably healthy, 375 individ-
uals (13.6%) had rectal bleeding and 120 individuals
(4.4%) had changes in bowel habits. The median and
mean sCD26 concentration for individuals with rectal
bleeding was higher compared to individuals without
the symptom, although no significant differences were
observed (p = 0.663). The standard deviation of the
mean was almost 1.5 times higher in persons with rectal
bleeding, indicating more disperse sCD26 concentra-
tion. For individuals with changes in bowel habits, the
mean concentration and standard deviation were also
higher compared to individuals without the symptom,
though the difference was not significant (p = 0.968).
Other digestive pathologies were also present in the
cohort studied, corresponding to a 13.7% of the pop-
ulation. The digestive pathologies were classified as
non-inflammatory benign pathologies (haemorrhoids,
diverticula, irritable bowel syndrome, anal fissure and
duodenal ulcer) and inflammatory benign pathologies,
as shown in Table 2. An additional group was included
for individuals who reported having a digestive pathol-
ogy, with no further information given. The highest
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Table 2
Relationship between personal history, family history and symptoms with the sCD26 levels (ng/mL)
Personal or family history n sCD26 sCD26 sCD26 ANOVA
range median mean ± SD p-value
P. history of cancer No 2,699 118–3,062 522.0 556.5 ± 182.6 0.309
Yes 55 238–785 532.0 526.0 ± 129.8
P. history of CRC No 2,748 118–3,062 522.0 556.0 ± 181.8 0.995
Yes 6 334–713 461.0 477.8 ± 127.2
P. history of polyps No 2,674 118–3,062 513.0 556.4 ± 181.8 0.408
Yes 80 252–1,277 523.0 537.8 ± 178.1
F. history of polyps No 2,651 118–3,062 522.0 556.0 ± 183.4 0.809
Yes 103 307–1,004 516.0 553.3 ± 130.0
F. history of cancer No 2,026 118–3,062 521.5 559.4 ± 193.6 0.355
Yes 728 164–1,169 523.0 546.0 ± 143.0
Symptoms or pathologies n sCD26 sCD26 sCD26 ANOVA
range median mean ± SD p-value
Rectal bleeding No 2,379 118–2,648 522.0 552.9 ± 171.2 0.663
Yes 375 288–3,062 531.0 574.9 ± 237.4
Change bowel habits No 2,634 118–3,062 522.0 555.4 ± 179.0 0.968
Yes 120 318–2,349 517.0 566.9 ± 234.3
Haemorrhoids No 2,661 118–3,062 522.0 554.4 ± 177.9 0.203
Yes 93 337–2,349 531.0 597.1 ± 266.4
Diverticula No 2,751 118–3,062 522.0 555.8 ± 181.8 1.000
Yes 3 485–712 583.0 593.3 ± 113.9
Irritable bowel syndrome No 2,740 118–3,062 519.0 550.4 ± 181.0 < 0.001∗
Yes 14 346–916 495.5 551.7 ± 164.8
Anal fissure No 2,744 118–3,062 518.0 549.5 ± 180.2 < 0.001∗
Yes 10 471–1,169 548.5 652.8 ± 224.1
Duodenal ulcer No 2,745 118–3,062 518.0 550.7 ± 180.9 0.0916
Yes 9 259–733 537.0 516.7 ± 168.4
Inflammatory benign pathologies No 2,749 118–3,062 522.0 555.9 ± 181.8 < 0.001∗
Yes 5 425–808 519.0 555.4 ± 154.7
Other not specified digestive pathologies No 2,377 118–3,062 519.0 572.0 ± 195.8 0.117
Yes 243 252–2,052 538.0 552.5 ± 176.1
P: personal; F: family; *statistically significant (p < 0.05).
sCD26 mean was observed within the 93 individuals
with haemorrhoids, who like the individuals with rectal
bleeding and changes in bowel habits, showed a stan-
dard deviation over 200 ng/mL. Individuals with diver-
ticula showed the highest median, with a mean similar
to the haemorrhoid group. Regarding pathologies as
irritable bowel syndrome and anal fissure, as well as the
inflammatory benign pathologies, and in contrast to the
rest of the groups, statistically significant differences
in the sCD26 levels were detected (p < 0.001). Differ-
ences were not observed for individuals with other not
specified benign pathologies.
Information concerning the smoking status was al-
so obtained from the cohort (Table 3). A 63.8% of
the individuals were non-smokers, 27.8% were current
smokers while 8.4% were former smokers. Current
smokers showed the lowest median and mean sCD26
concentration, while the highest values corresponded
to former smokers. The Kruskal-Wallis test revealed
statistically significant differences in the sCD26 levels
between the three groups considered (p = 0.013). Ac-
cording to the Dunn’s test, differences exist between
current smokers and non-smokers (71.5 > 3.9), current
smokers and former smokers (165.2 > 6.8) and non-
smokers and former smokers (93.7 > 6.4). Additional-
ly, we tested if the number of cigarettes per day was al-
so related to the sCD26 concentration: according to the
groups 1–5, 6–10, 10–20 and > 20 cigarettes per day,
there was no significant difference. Further analyses
with the Dunn’s test showed differences in the sCD26
between the groups 1–5 vs. 6–10, and any of the groups
vs. >20 cig/day.
4. Discussion
In previous works we observed that the soluble CD26
levels were diminished in CRC patients as compared to
healthy donors [2,7] suggesting its utility in the early
diagnosis of CRC and advanced adenomas (manuscript
submitted). In this work we measured the sCD26 con-
centration in the sera of a large cohort of apparently
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Table 3
Relationship between tobacco smoking and the sCD26 levels (ng/mL)
Smoking status n sCD26 sCD26 sCD26 Kruskal-Wallis
range median mean ± SD p-value
Non-smoker 1,758 118–3,062 524.0 557.2 ± 175.7 0.013
Former smoker 230 189–1,448 545.0 576.8 ± 192.6
Current smoker 766 164–2,648 510.0 546.6 ± 191.3
1–5 cig/day 238 274–2,349 505.5 550.3 ± 184.0 0.393
6–10 cig/day 153 176–2,648 516.0 547.1 ± 231.5
10–20 cig/day 256 164–2,052 506.0 534.7 ± 180.1
> 20 cig/day 119 288–1,244 523.5 568.6 ± 173.0
Cig/day: cigarettes smoked per day.
healthy individuals to evaluate its relation with certain
epidemiologic variables and to establish the feasibil-
ity of its use as a test for the diagnosis of CRC and
premalignant lesions.
Since this is the first time sCD26 was measured in a
large cohort with these characteristics, we corroborated
that the concentration of this glycoprotein in serum has
a normal distribution. The mean sCD26 concentration
in this cohort corresponded to 555.9 ± 181.7 ng/mL,
similar to that previously reported for 52 healthy donors
(559.7 ± 125.5 ng/mL) [7]. However, the range in this
large cohort was considerably broad compared to that
of the healthy donors (118–3,062 ng/mL and 273–863
ng/mL, respectively) [7], resulting in a larger standard
deviation. In relation to the data reported by the kit
manufacturer in 38 apparently healthy donors (mean:
591 ± 179 ng/mL; range: 296.0–1,110 ng/mL), the
standard deviation is comparable in both cohorts, al-
though the mean sCD26 concentration is higher in the
kit-reported healthy population.
The analysis of the sCD26 concentration in the large
cohort studied showed no association with the gender
of the individuals, though it should be noticed there
was a small number of females in this cohort and thus
this conclusion should be taken cautiously. However,
women tend to have higher median and mean sCD26
levels despite the narrower range of concentration com-
pared to males, in contrast to that found when enzy-
matic activity was measured in plasma or serum [9,10].
This difference can be explained by putative changes
in the glycosylation pattern (leading to a lack of im-
munorecognition of sCD26), the purported presence
of the DPP-IV activator attractin, or the secretion of
DPP-II [4,10].
Regarding age, no differences were observed in this
cohort comparing the sCD26 levels in individuals < 50
and  50 years of age. Although the analysis between
decades revealed certain differences in the sCD26 lev-
els, the decrease in the glycoprotein concentration be-
tween the fourth, fifth and sixth decade of life is very
slight and would not interfere with the sCD26 test ap-
plied to a screening population, especially older than
50 years. Concerning the DPP-IV enzymatic activity
present in serum, it was previously reported for a co-
hort of 481 individuals with ages ranging from 19 to 61
years a relationship with age [9,10].
On the other hand, no association was found between
the sCD26 concentration and the personal or familial
history of polyps, CRC or cancer other than CR. Al-
though the mean sCD26 levels were somewhat dimin-
ished in individuals with these antecedents.
Regarding digestive diseases, the groups with irri-
table bowel syndrome, anal fissure and inflammatory
benign pathologies had an association with the sCD26.
Although the biological role of the sCD26 has not
been completely elucidated yet, it has been proposed
to be multifunctional. Some of the functions becom-
ing quite clear are the activation-deactivation of some
chemokines [5,13] and a T-cell activation through a
CD86 upregulation [14], which supports sCD26 has a
relationship with the immune response and/or inflam-
mation. On the contrary, the relationship of the sCD26
levels with irritable bowel syndrome and anal fissure
is not straightforward, and more details on the biolog-
ical functions of the sCD26 are needed to find a rea-
sonable explanation. On the other hand, sCD26 levels
were found to be related to the smoking status, smokers
showing the lowest mean although no clear associa-
tion regarding the amount of cigarettes smoked per day
was observed. Tobacco smoking was also included in
our analysis due to the consistent association between
smoking and a significantly increased risk of CRC [12,
18].
The absence of correlation between all the param-
eters analysed, with special interest on the personal
and familial history, together with rectal bleeding and
changes in bowel habits, confirm that the sCD26 test
can be easily offered and evaluated in a large popu-
lation cohort at least predominantly formed by males
over 50 years, which coincides with one of the popu-
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lation sectors considered at average risk for CRC [11].
The information elucidated in this study appears to be
essential for the future application of the sCD26 test
for screening and case-finding purposes. The next step
in the validation of this molecule as a tumour marker
is undoubtedly a screening study in average-risk indi-
viduals, perhaps along with the comparison of a faecal
occult blood test.
Moreover, it should be noted that the alteration of the
sCD26 levels as a tumour marker for early diagnosis of
CRC and pre-malignant lesions has an independent ori-
gin to that of faecal blood appearance and, if not to the
tumourigenic locus, at least to the tumourigenic tissue.
In addition, as it seems immune-related, the sCD26 de-
crease in the plasma of patients should be sooner in
the adenoma-carcinoma development compared to the
presence of faecal blood.
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